CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,380 enrolled
Drug / intervention
Tirofiban +1 moredrug
Likely dose
Tirofiban 5μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06265051
NCT06265051Phase 3Completed

Safety and Efficacy of Adjunct Tirofiban Treatment After Successful Mechanical Thrombectomy Recanalization in Acute Anterior Circulation Ischemic Stroke- A Multicenter, Prospective, Double-blind, Randomized Trial

Xiang Luo·interventional·Posted Feb 20, 2024·Updated Mar 11, 2026

In Brief

A Phase 3 clinical trial evaluating Tirofiban and Saline placebo for Acute Ischemic Stroke and Vessel Occlusion. Completed, enrolled 1,380 participants across 1 site.

Detailed Summary

Acute ischemic stroke with large vessel occlusion is a frequently occurring life-threatening condition. Although endovascular treatment can effectively open occluded vessels, the successful reperfusion rate exceeds 80%, but the rate of good prognosis is less than 50%. The current clinical focus is on how to improve futile recanalization. Tirofiban is widely used in the treatment of stroke, as it can effectively prevent vascular reocclusion and improve microcirculation perfusion. It has the potential to improve futile recanalization, but there is a lack of high-level evidence-based medical support. This multicenter, prospective, double-blind, randomized controlled trial was conducted to assess the effectiveness and safety of sequential tirofiban therapy following successful mechanical thrombectomy within 24 hours of onset.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsFujian Medical University Union Hospital, Jingzhou Hospital Affiliated to Yangtze University, Xiangyang No 1 People's Hospital Affiliated to Hubei University of Medicine, Puren Hospital Affiliated to Wuhan University of Science and Technology, Zhongnan Hospital, First Affiliated Hospital of Fujian Medical University, Wuhan Central Hospital, Xianning Central Hospital, Shanxi Provincial People's Hospital, The Third People's Hospital of Hubei Province, Jingmen Central Hospital, Hubei University of Medicine, Wuhan No.1 Hospital, Nanyang Central Hospital, Yichang Central People's Hospital of China Three Gorges University, The Central Hospital of Huanggang, Zoucheng City People's Hospital, Qujing Central Hospital of Yunnan Province, Taihe Hospital, Affiliated Hospital of Hubei Province of Medicine, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Nanchang University, Central Hospital of Xiaogan, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Huangshi Central Hospital, Zigong No.1 Peoples Hospital, Xiangyang Hospital of Traditional Chinese Medicine, The First People's Hospital of Jingzhou City, First People's Hospital of Xianyang, Jiujiang No.1 People's Hospital, Zhongxiang Hospital of Traditional Chinese Medicine, Jiangxi Provincial People's Hopital, The Lichuan ethnic Hospital of Traditional Chinese Medicine, Xiangyang Central Hospital People's Hospital of Huangpi District, Quanzhou First Hospital, Minda Hospital of Hubei Minzu University, The Cerebrovascular Hospital of Hubei Province, The First People's Hospital of Changde City, Longyan First Affiliated Hospital of Fujian Medical University, Xiangzhou People's Hospital, Jingmen People's Hospital, The First People's Hospital of TianMen in Hubei Province, Hanyang Hospital Affiliated to Wuhan University of Science and Technology, Tongcheng People's Hospital, Gaoyou People's Hospital, Zaoyang First People's Hospital, CR & WISCO General Hospital, Wuhan Hankou Hospital, Lu'an People's Hospital of Anhui Hospital, Yingtan People's Hospital, Shiyan Renmin Hospital, Dali Bai Autonomous Prefecture People's Hospital, Three Gorges Hospital of Chongqing University, The Second People's Hospital of Jingzhou City, General Hospital of the Yangtze River Shipping, The Affiliated Hospital Of Southwest Medical University, Fujian Provincial Hospital, Zhongxiang People's Hospital, LiuZhou People's Hospital, The Fifth Hospital of Wuhan, Xiaogan First People's Hospital, Loudi Central Hospital, Ezhou Central Hospital, Second Xiangya Hospital of Central South University, Qingdao Central Hospital, Taizhou First People's Hospital, Renmin Hospital of Wuhan University, Hubei Provincial Hospital of Integrated Chinese & Western Medicine, The First Affiliated Hospital of BaoTou Medical College, Xianfeng People's Hospital, Wuhan Third Hospital, The Fourth Hospital of Wuhan, Chengdu Fifth People's Hospital, Xingyi People's Hospital, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shenzhen Hospital of Southern Medical University, The Third People's Hospital of Jingzhou City, The First People's Hospital of Jiangxia District, Xihua People's Hospital, Shanghai East Hospital

Timeline

Phase 3CompletedFinished
20252026
First PostedFeb 20, 2024
Enrollment StartApr 9, 2024
Primary CompletionDec 29, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 2.4 years ago

Interventions

Tirofibandrug

After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Tirofiban 5μg/kg was administered intravenously through the catheter artery at a rate of 1ml/min, followed by an intravenous infusion of 0.1μg/(kg·min) for 24 hours. Standard medical treatment was administered after the surgery.

Saline placebodrug

After the completion of endovascular treatment and successful recanalization (mTICI 2b/3), the patients were randomly assigned to the experimental group. Saline placebo was administered in the same manner as tirofiban group. Standard medical treatment was administered after the surgery.